EXHIBIT 31.1



CERTIFICATION



I, Kenneth L. Waggoner, certify that:



1. I have reviewed
this Amendment No. 3 to the Annual Report on Form 10-K/A of PharmaCyte Biotech, Inc. (“Report”) and its subsidiaries
for the fiscal year ended April 30, 2015;



2. Based on my
knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this Report;



3. Based on my
knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
Report;



4. The registrant’s
other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:



(a) Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this Report is being prepared;



(b) Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles in the United States;



(c) Evaluated the
effectiveness of the registrant’s disclosure controls and procedures and presented in this Report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such
evaluation;



(d) Disclosed in
this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5. The registrant’s
other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing
the equivalent functions):



(a) All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



(b) Any fraud,
whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.





|Dated: March 2, 2016 |  | By: | /s/ Kenneth L. Waggoner                                                                                                                            
|-------------------- |  | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------
|                     |  |     | Name:  Kenneth L. Waggoner                                                                                                                         
|                     |  |     | Title:  Principal Executive Officer and acting
        Principal
        Financial and Principal
        Accounting Officer on behalf of Registrant